Clinical Trial Update: Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating Doxorubicin, Cyclophosphamide, and Paclitaxel with or without Bevacizumab in patients with lymph node-positive or high-risk lymph node-…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• Doxorubicin (doxorubicin)
• PACLITAXEL (PACLITAXEL)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Breast Adenocarcinoma | Phase 3 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2019-09-04